News | February 23, 2026
Bavarian Nordic bags $22.5M Canadian vaccine order
The order will cover the manufacturing of bulk vaccine in 2026
The order will cover the manufacturing of bulk vaccine in 2026
Net sales reached CHF 1,327.8 million, up 2.6% year-on-year in Swiss francs, or 4.3% at constant exchange rates
The alliance directly links VivaMed’s computational drug hypotheses with Syngene’s preclinical development capabilities
Merck is currently conducting approximately 80 Phase 3 studies, and the company expects more than 20 new growth drivers over next several years, almost all with blockbuster potential
The drug’s safety profile in LIBRETTO-432 aligned with previous selpercatinib studies, showing no unexpected concerns
If approved, TEV-'749 could help address a significant unmet need in available schizophrenia treatment options by addressing the lack of viable long-acting olanzapine formulations
Expansion at the Oss (NL) site adds capacity and R&D capabilities, supporting the development and manufacturing of ADCs and other novel bioconjugates from First-in-Human to commercialization
The approval, based on results from the Phase 3 AMPLIFY trial, marks the first all-oral, fixed-duration regimen for first-line CLL therapy
The NDA filing is supported by results from the phase III evERA Breast Cancer study
The results mark a potential breakthrough for patients living with CIndU, a condition with limited treatment options
Subscribe To Our Newsletter & Stay Updated
